It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price ...

In trading on Tuesday, shares of Axsome Therapeutics Inc (Symbol: AXSM) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $107 per share. By ...

On the other hand, Axsome Therapeutics’ AXSM shares declined after announcing results from a study on major depressive disorder (MDD). Shares of Corcept Therapeutics Incorporated surged on March ...

Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...

Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...